Zealand Pharma announced positive topline results for dapiglutide, a dual GLP-1/GLP-2 receptor agonist, in overweight and obese adults.
In Part 2 of the phase 1b multiple ascending dose trial, dapiglutide led to a mean weight loss of 11.6% after 28 weeks of once-weekly injections, with no required lifestyle changes45.
Participants (n=30, 93% male, median age 44.5 years, median baseline weight 91.9 kg, median BMI 28.8 kg/m²) were randomized 2:
1 to receive dapiglutide (up to 26 mg weekly) or placebo45.
Weight loss in the dapiglutide group (11.6%) significantly exceeded that of the placebo group (0.2%)45.
No severe or serious side effects were reported. The most common adverse events were nausea and vomiting5.
The positive results position dapiglutide's efficacy as comparable to leading GLP-1 treatments, despite the predominance of male and relatively lean participants in the trial5.
Sources:
4. https://www.patientcareonline.com/view/dual-glp-1-glp-2-agonist-dapiglutide-achieves-11-6-mean-weight-loss-at-28-weeks-in-phase-1b-trial
5. https://medwatch.com/News/Pharma_Biotech/article18290369.ece